↓ Skip to main content

Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’

Overview of attention for article published in PharmacoEconomics, February 2018
Altmetric Badge

Mentioned by

twitter
1 X user
facebook
1 Facebook page

Readers on

mendeley
19 Mendeley
Title
Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’
Published in
PharmacoEconomics, February 2018
DOI 10.1007/s40273-018-0620-y
Pubmed ID
Authors

Amir Ansaripour, Carin A. Uyl-de Groot, W. Ken Redekop

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 19 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 26%
Student > Master 3 16%
Other 2 11%
Lecturer 2 11%
Student > Postgraduate 2 11%
Other 3 16%
Unknown 2 11%
Readers by discipline Count As %
Medicine and Dentistry 7 37%
Pharmacology, Toxicology and Pharmaceutical Science 3 16%
Nursing and Health Professions 2 11%
Agricultural and Biological Sciences 1 5%
Biochemistry, Genetics and Molecular Biology 1 5%
Other 2 11%
Unknown 3 16%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 February 2018.
All research outputs
#18,585,544
of 23,020,670 outputs
Outputs from PharmacoEconomics
#1,653
of 1,862 outputs
Outputs of similar age
#331,984
of 442,600 outputs
Outputs of similar age from PharmacoEconomics
#31
of 37 outputs
Altmetric has tracked 23,020,670 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,862 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one is in the 3rd percentile – i.e., 3% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 442,600 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.